OncRef

Clinical Trial: NCT03546361

CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 1

Lead Sponsor:Jonsson Comprehensive Cancer Center
Information Provided By:Jonsson Comprehensive Cancer Center
Last Update Posted:2025-01-14

Study Overview

Brief Summary

This phase I trial studies the side effects and best dose of autologous dendritic cell-adenovirus CCL21 vaccine (CCL21-gene modified dendritic cell vaccine) combined with intravenous pembrolizumab, and to see how well they work in treating patients with stage IV non-small cell lung cancer. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving CCL21-gene modified dendritic cell vaccine with pembrolizumab may work better in treating patients with stage IV non-small cell lung cancer.

Official Title

A Phase I Trial of Intratumoral Administration of CCL21-Gene Modified Dendritic Cell (Ad-CCL21-DC) Combined With Intravenous Pembrolizumab for Advanced NSCLC

Conditions

Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8

Intervention / Treatment

  • Biological: Autologous Dendritic Cell-Adenovirus CCL21 Vaccine
  • Biological: Pembrolizumab

Other Study ID Numbers

  • 17-000174
  • NCI-2018-01244
  • HEMONC CIRM IST Lung
  • K08CA245249

Start Date (Actual)

2019-07-08

Primary Completion Date (Estimated)

2026-01-11

Study Completion Date (Estimated)

2027-01-11

Enrollment (Actual)

24

Study Type

Interventional

Phase

Phase 1